Huakang Shares released its 2026 semi-annual report. First-half operating revenue was 2.481 billion yuan, up 32.98% year on year, but net profit attributable to the parent was only 41.964 million yuan, down 68.61% year on year. After excluding non-recurring items, net profit attributable to the parent was 33.0809 million yuan, a sharp drop of 72.78% from 122 million yuan in the same period last year. The company's gross margin was 12.15%, down 5.65 percentage points year on year. Period expenses rose to 233 million yuan, of which financial expenses were 68.9028 million yuan, up 87.55% year on year, mainly because interest expenses on convertible bonds continued to be recognised and foreign exchange losses increased substantially. As of the end of June 2026, the book value of the company's accounts receivable reached 723 million yuan, an increase of 22.97% from the end of 2025, with the top five customers accounting for 46.94% of total accounts receivable.
Zhejiang Huakang Pharmaceutical Co LtdFirst-half net profit fell 68.61% year-on-year, with gross margin down and financial expenses surging.
